Acer Therapeutics (ACER)
(Delayed Data from OTC)
$0.66 USD
0.00 (0.00%)
Updated Nov 20, 2023 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Acer Therapeutics Inc. [ACER]
Reports for Purchase
Showing records 61 - 80 ( 213 total )
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Receives Favorable Pre-NDA Meeting Minutes - No Surprise Requests
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
1Q21: More ACER-001 Regulatory Progress, ACER-801 Trial Starts By YE21
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
1Q21: More ACER-001 Regulatory Progress, ACER-801 Trial Starts By YE21
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Finalizes Global ACER-001 Collaboration with Relief, Now Well-Funded
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
4Q20: Expecting ACER-001 NDA Filing Mid-2021, Rest of Pipeline Progresses
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Biotechnology: Invitation: Virtual 33rd Annual Roth Conference (March 15-17)
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
UCD/MSUD Drug ACER-001 Shows Bioequivalence to Buphenyl in Fed Volunteers
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Signs Global ACER-001 Option Agreement with Relief Therapeutics
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
New Publication Lends Further Support to Celiprolol Conferring Protection
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
New Publication Shows NaPB Utility on Top of Acute MSUD Protocol Regimen
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J